<DOC>
	<DOCNO>NCT02081716</DOCNO>
	<brief_summary>CMV one important opportunistic infection transplant recipient . In South Korea , 95 % adult reveal sero-positivity CMV IgG . Until , sero-positivity CMV IgG bone marrow organ transplantation laboratory test choice stratify risk CMV reactivation solid organ transplantation . Theoretically , CMV-specific cell-mediate immune response bone marrow transplantation categorize patient high low risk CMV development bone marrow transplantation . The investigator thus evaluate usefulness CMV-specific ELISPOT assay bone marrow transplant candidate predict development CMV infection transplantation .</brief_summary>
	<brief_title>Assessment CMV-specific ELISPOT Assay Predicting CMV Infection Bone Marrow Transplant Recipients ( ACE-BMT )</brief_title>
	<detailed_description>We evaluate whether CMV-specific cell-mediated immune response transplant , 1 month , 3 month , 6 month transplantation predict CMV infection bone marrow transplantation .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>age 16 agree write informed consent exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>